• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Enovis™ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS 2025

    3/25/25 8:00:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care
    Get the next $ENOV alert in real time by email

    WILMINGTON, DE, March 25, 2025 (GLOBE NEWSWIRE) -- Enovis™ (NYSE:ENOV), a global medical technology innovator, will feature its expanding portfolio of foot and ankle solutions at this year's American College of Foot & Ankle Surgeons (ACFAS) Annual Scientific Conference in Phoenix, Ariz., taking place March 27-30.

    Coupled with evidence-based technologies, Enovis Foot & Ankle will spotlight its commitment to surgeon education and hands-on training, reinforcing its mission to Redefine Every Step. "We're transforming what partnership means in foot and ankle surgery," said Gary Justak, President and General Manager of Enovis Foot & Ankle. "Beyond innovative implants and advanced technologies, we provide the training, tools, and collaboration surgeons need to enhance surgical outcomes and restore motion for patients—every step of the way."

    The new Tarsoplasty Percutaneous Lapidus Correction System—an innovative approach to Lapidus bunionectomy—will be among the solutions featured. "Tarsoplasty provides foot and ankle surgeons a percutaneous Lapidus option through a controlled, reproducible system," said Bradley P. Abicht, DPM, FACFAS. "By reducing the surgical footprint, this technique enhances a patient's perioperative experience."

    The array of advanced solutions shown will include:

    • Tarsoplasty™, an innovative, percutaneous approach to Lapidus bunionectomy.
    • OssiGraft Prime™,  viable bone matrix allografts meeting strict organ donation guidelines.
    • Aircast® AirSelect™ Elite, Enovis' most advanced pneumatic walking boot.
    • Velocity+®, proximal extension cuff that provides added stability.
    • Regeneration OL1000™, non-invasive, fracture nonunion bone growth stimulator.

    Enovis will also highlight new research that compares the Arsenal Foot™ Plating System's 30° screw angulation to 0–15°, examining how angulation, insertion sequence, and plate design influence compression and contact area—key factors in achieving stable fixation. A white paper with more information will be available at the Enovis booth.

    Beyond the conference, Enovis invites attendees to two engagements bringing together leading experts to explore innovations transforming foot and ankle surgery. Enovis will host Phoenix Rising: Foot & Ankle Edition on March 28 from 6-9 p.m.; register here. Additionally, Enovis is sponsoring the Flatfoot/MIS Techniques Workshop (Cadaveric) on March 26, 1-5 p.m.

    Visit booth 1820 to engage with Enovis products firsthand; for live updates during the conference, follow @enovisfootankle on Instagram and Enovis Foot & Ankle on LinkedIn.

    About Enovis

    Enovis Corporation (NYSE:ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company's extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company's shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. For more information about Enovis, please visit www.enovis.com.

    *Dr. Abicht is a paid consultant of Enovis.

    Media Contact

    Rachel Colloff

    Director, Corporate Communications

    [email protected]



    Attachment

    • Enovis Featured Products at ACFAS 2025


    Primary Logo

    Get the next $ENOV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ENOV

    DatePrice TargetRatingAnalyst
    10/3/2024$62.00Mkt Outperform
    JMP Securities
    6/13/2024$53.00Neutral
    JP Morgan
    2/13/2024$72.00Overweight
    Stephens
    1/22/2024$75.00Buy
    UBS
    1/3/2024Outperform
    William Blair
    12/15/2023$62.00 → $70.00Buy
    Needham
    10/20/2023$75.00Buy
    ROTH MKM
    6/26/2023$70.00Buy
    Needham
    More analyst ratings

    $ENOV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Enovis Announces First Quarter 2025 Results

      Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12th, 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. First Quarter 2025 Financial Results Enovis' first-quarte

      5/8/25 6:00:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Enovis to Host First Quarter 2025 Results Conference Call on May 8th

      Wilimington, DE, April 17, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on Thursday, May 8th, 2025 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 335

      4/17/25 7:00:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Enovis Announces Appointment of Damien McDonald as Chief Executive Officer

      Damien McDonald appointed CEO, effective as of May 12, 2025Company reiterates guidance for first quarter revenues and aEBITDA WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "The Company") (NYSE:ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company's 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at th

      4/2/25 6:30:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Shirley Brady was granted 829 shares, increasing direct ownership by 0.84% to 99,196 units (SEC Form 4)

      4 - Enovis CORP (0001420800) (Issuer)

      4/11/25 9:30:04 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Director Lalor Angela S was granted 589 shares, increasing direct ownership by 5% to 13,237 units (SEC Form 4)

      4 - Enovis CORP (0001420800) (Issuer)

      4/1/25 9:00:07 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • SVP, Chief Financial Officer Berry Phillip Benjamin (Ben) was granted 24,137 shares, increasing direct ownership by 76% to 55,983 units (SEC Form 4)

      4 - Enovis CORP (0001420800) (Issuer)

      3/11/25 9:00:16 PM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    Financials

    Live finance-specific insights

    See more
    • Enovis Announces First Quarter 2025 Results

      Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12th, 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. First Quarter 2025 Financial Results Enovis' first-quarte

      5/8/25 6:00:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Enovis to Host First Quarter 2025 Results Conference Call on May 8th

      Wilimington, DE, April 17, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on Thursday, May 8th, 2025 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 335

      4/17/25 7:00:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Enovis Announces Fourth Quarter and Full Year 2024 Results

      Continued commercial momentum with fourth-quarter sales growth of 23% on a reported basis and strong adjusted EBITDA margin expansion Fourth-quarter Reconstructive sales grew 59% year-over-year on a reported basis and 10% on a Comparable Sales basis Exceeded year one commercial and integration plans for Lima Wilmington, DE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. F

      2/26/25 6:01:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    Leadership Updates

    Live Leadership Updates

    See more
    • Enovis Announces Appointment of Damien McDonald as Chief Executive Officer

      Damien McDonald appointed CEO, effective as of May 12, 2025Company reiterates guidance for first quarter revenues and aEBITDA WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "The Company") (NYSE:ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company's 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at th

      4/2/25 6:30:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Maplebear Set to Join S&P MidCap 400; Enovis to Join S&P SmallCap 600

      NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Maplebear Inc. (NASD: CART) will replace Enovis Corp. (NYSE:ENOV) in the S&P MidCap 400, and Enovis will replace Arch Resources Inc. (NYSE:ARCH) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 14. S&P SmallCap 600 constituent CONSOL Energy Inc. (NYSE:CEIX) is acquiring Arch Resources in a deal expected to be completed soon, pending final closing conditions. Following completion of the merger, CONSOL Energy will be renamed Core Natural Resources Inc., and its ticker will change to CNR. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index

      1/7/25 6:19:00 PM ET
      $ARCH
      $CART
      $CEIX
      $ENOV
      Coal Mining
      Energy
      Business Services
      Consumer Discretionary
    • Enovis Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies

      WILMINGTON, DE, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Enovis™ (NYSE:ENOV), an innovation-driven medical technology growth company, is pleased to announce the appointment of Tim Czartoski to the position of President, U.S. Surgical and Global Product and Enabling Technologies. Mr. Czartoski has direct responsibility for the Company's U.S. Surgical business, including the global surgical product engine and enabling technologies. He reports to Louie Vogt, Group President of Enovis' Reconstructive (Recon) Business Group. Mr. Czartoski is a successful MedTech executive with over 22 years of experience at Depuy Synthes, the Orthopaedics Company of Johnson & Johnson, where he progressed in le

      9/9/24 3:50:00 PM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    SEC Filings

    See more
    • SEC Form 10-Q filed by Enovis Corporation

      10-Q - Enovis CORP (0001420800) (Filer)

      5/8/25 5:14:27 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Enovis Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Enovis CORP (0001420800) (Filer)

      5/8/25 6:19:47 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • SEC Form DEF 14A filed by Enovis Corporation

      DEF 14A - Enovis CORP (0001420800) (Filer)

      4/11/25 4:01:52 PM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Enovis Corporation

      SC 13G/A - Enovis CORP (0001420800) (Subject)

      11/14/24 1:28:31 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

      SC 13G/A - Enovis CORP (0001420800) (Subject)

      4/5/24 12:21:51 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

      SC 13G/A - Enovis CORP (0001420800) (Subject)

      2/14/24 10:04:36 AM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JMP Securities initiated coverage on Enovis Corporation with a new price target

      JMP Securities initiated coverage of Enovis Corporation with a rating of Mkt Outperform and set a new price target of $62.00

      10/3/24 7:29:21 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • JP Morgan initiated coverage on Enovis Corporation with a new price target

      JP Morgan initiated coverage of Enovis Corporation with a rating of Neutral and set a new price target of $53.00

      6/13/24 7:06:52 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Stephens initiated coverage on Enovis Corporation with a new price target

      Stephens initiated coverage of Enovis Corporation with a rating of Overweight and set a new price target of $72.00

      2/13/24 6:34:49 AM ET
      $ENOV
      Industrial Specialties
      Health Care